Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249813 | 0.90 | TSHR (0.42) | TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL25764177 | 0.85 | TSHR (0.46) | TSHRPHF8KDM2A | |
| SCHEMBL19249812 | 0.84 | HRH3 (0.40) | TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL25763425 | 0.79 | TSHR (0.41) | TSHRPHF8KDM2A | |
| SCHEMBL22640989 | 0.79 | L3MBTL1 (0.36) | TSHRL3MBTL1 | |
| SCHEMBL19249810 | 0.79 | TSHR (0.33) | TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL17256253 | 0.78 | TSHR (0.41) | TSHRPOLB | |
| SCHEMBL21236783 | 0.76 | ALDH1A1 (0.35) | TSHRL3MBTL1ALDH1A1 | |
| SCHEMBL21291271 | 0.76 | TSHR (0.48) | TSHRL3MBTL1ALDH1A1LMNA | |
| SCHEMBL24709265 | 0.76 | TSHR (0.38) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-22 | — | — | US | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | DCLRE1A, DTYMK, RTCB | TSHR 3215/4885CYP1A2 4421/4885CYP2D6 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.